Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage

Hanayo Kawai1, Waichi Sato, Yukio Yuzawa

  • 1Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.

Insights

Midkine promotes cisplatin-induced kidney damage by increasing inflammation and neutrophil infiltration. Reducing midkine levels improves survival rates in mice treated with cisplatin, highlighting its role in nephrotoxicity.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Toxicology

Background:

  • Cisplatin causes proximal tubule epithelial cell death, but secondary effects like inflammation are poorly understood.
  • Midkine, a growth factor in proximal tubules, has dual roles in cisplatin nephrotoxicity, including anti-apoptotic and chemotactic activities.

Purpose of the Study:

  • To investigate the role of midkine in cisplatin-induced nephrotoxicity.
  • To elucidate the mechanisms by which midkine influences renal damage and survival.

Main Methods:

  • Comparison of survival rates and kidney injury markers between midkine-deficient and wild-type mice after cisplatin administration.
  • Assessment of neutrophil infiltration and apoptosis.
  • Intervention using midkine anti-sense oligodeoxyribonucleotide to suppress midkine expression.

Main Results:

  • Midkine-deficient mice exhibited significantly higher survival rates and lower blood urea nitrogen levels compared to wild-type mice.
  • Wild-type mice showed enhanced neutrophil recruitment, correlating with midkine's chemotactic activity.
  • Suppression of midkine expression reduced neutrophil infiltration and subsequent kidney damage.

Conclusions:

  • Early midkine expression triggers an inflammatory response, leading to proximal tubule cell death and exacerbating cisplatin nephrotoxicity.
  • Inflammation plays a critical role in cisplatin-induced renal damage.
  • Midkine represents a potential molecular target for preventing cisplatin-induced kidney injury.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...